Transforming refractory cancer treatment-induced thrombocytopenia management: a real-world retrospective cohort study of fixed-dose romiplostim
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Treatment options for refractory cancer therapy-induced thrombocytopenia (R-CTIT) are limited. This real-world retrospective cohort study evaluated the effectiveness and safety of fixed-dose romiplostim in patients with R-CTIT. Methods In this retrospective analysis, 28 patients with R-CTIT received romiplostim (250 μg/week) at our center (2023–2024). Outcomes included time to response, platelet increase, bleeding score, transfusion independence, and safety. Results Median time to platelet response was 7 days. By week 3, platelet counts rose from 19 × 10 9 /L to 136 × 10 9 /L ( P < 0.001), with an objective response rate (ORR) of 92.9% (26/28; 75% complete response). At week 8, responses were sustained (ORR 92.9%; platelets 108 × 10 9 /L, P < 0.001). Bleeding scores improved; 93.3% achieved platelet transfusion independence. Hemoglobin increased (90 g/L to 112 g/L, P = 0.029), with a trend toward higher neutrophils. Twenty responders resumed anticancer therapy. After romiplostim discontinuation (n = 7), 71.4% experienced recurrent grade IV thrombocytopenia. Three patients (10.7%) developed deep vein thrombosis. Conclusion Fixed-dose romiplostim (250 μg/week) induces rapid and durable platelet responses, improves bleeding and hematologic parameters, and facilitates continued anticancer therapy in R-CTIT in this real-world retrospective cohort. Thrombocytopenia commonly recurs after stopping, and thrombotic risk warrants monitoring. Prospective studies with larger samples and a control group are needed to confirm these findings.
Source: Frontiers in Pharmacology
Institution: Jilin University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236749629
